PDCD1 and melanoma: The observed ORRs in this study for patients with melanoma who were PD-1–naïve (42.9%) or relapsed or refractory (4.7%) are in line with previous studies examining these patient settings [43.1% (RELATIVITY-047) for PD-1–naïve and 9.2% to 12.0%, (RELATIVITY-020) for relapsed or refractory; refs. 37, 38].